Metabolic & Endocrine Research

WWP-3X (Reta)

Price range: $220.00 through $952.00

Per vial
$22.00
10 vials per pack
Resale value
$66.00
per vial
Free shipping on orders over $2,000
$300 store credit on any independent COA · results don't matter
  • Delivery guarantee Reshipped free if it doesn't arrive
  • ≥99% purity Manufacturer-direct production
  • Store credit guarantee Send any COA result, get store credit

WWP-3X (Reta) - GLP-1 / GIP / Glucagon Triple Agonist

WWP-3X (Reta) is a synthetic research peptide that activates three different metabolic hormone receptors at once: GLP-1 (the same system targeted by semaglutide), GIP (a gut hormone that regulates insulin, also targeted by tirzepatide), and glucagon (the hormone that tells the body to release stored energy). Most compounds in this class hit one or two of these receptors - retatrutide is the first peptide to hit all three in a single molecule, which is why it is sometimes nicknamed “GLP-3” and is one of the most actively studied peptides in obesity and metabolic research.


Why Triple Agonism Matters

GLP-1 and GIP act mostly on the “intake” side of energy-balance signaling - satiety pathways, gastric emptying, and glucose-dependent insulin response. The glucagon receptor adds the “output” side: hepatic energy expenditure and lipid-metabolism signaling. Combining both arms in one molecule lets researchers study intake and expenditure signaling together rather than in isolation.

Receptor What it does in plain terms
GLP-1 Satiety signaling, gastric emptying, glucose-dependent insulin response
GIP Insulin-secretion signaling, GLP-1 signal amplification, adipose-tissue signaling
Glucagon Hepatic energy expenditure, lipid-metabolism and hepatic-lipid signaling

Retatrutide vs Tirzepatide vs Semaglutide

All three peptides come from the same research lineage, but they don’t hit the same receptors. A quick comparison of how they differ at the receptor level:

Compound GLP-1 GIP Glucagon Developer
Semaglutide Yes No No Novo Nordisk
Tirzepatide Yes Yes No Eli Lilly
Retatrutide Yes Yes Yes Eli Lilly

The practical research difference: tirzepatide added GIP to what semaglutide already did, and retatrutide added glucagon on top of that. Phase 2 trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) reported average weight reductions of about 24% at the highest retatrutide dose over 48 weeks, which is higher than what has been reported in equivalent-length trials of semaglutide or tirzepatide - though direct head-to-head studies are still ongoing.


Research Applications

Retatrutide is used in studies examining:

  • Body composition changes under sustained caloric restriction
  • How triple-agonist protocols compare to single or dual agonists like semaglutide and tirzepatide
  • Blood sugar and insulin response in metabolic models
  • Fat accumulation in the liver and its reversal (MASLD / NAFLD research)
  • Dose-response curves during gradual dose escalation
  • Cardiovascular and metabolic markers under extended exposure

Specifications

Format Lyophilized powder
Purity ≥99%
Aliases Reta, LY3437943, GLP-3
Available sizes 10mg · 20mg · 30mg
Storage 2-8°C unopened; stable 12+ months
Use Research purposes only - not for human use

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Solvent compatibility and stability parameters for Retatrutide are documented in the published peer-reviewed literature and standard peptide-chemistry references.


Reference Literature

Published clinical and preclinical Retatrutide literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.


Common Questions About Retatrutide Research

Is retatrutide different from semaglutide?

Semaglutide activates one receptor (GLP-1). Retatrutide activates three receptors (GLP-1, GIP, and glucagon) in a single molecule, which is the structural distinction studied in the metabolic-research literature.

What is the difference between retatrutide and tirzepatide?

Tirzepatide activates GLP-1 and GIP. Retatrutide activates those same two receptors plus glucagon. The added glucagon signaling is the structural difference between the two compounds at the receptor level.

Why is retatrutide sometimes called GLP-3?

“GLP-3” is an informal nickname used in the research community because retatrutide is the third-generation development in the GLP-1 / GLP-1+GIP / GLP-1+GIP+glucagon progression. It is not an official receptor name or a separate molecule - the technical label is “triple agonist” and the compound’s development code is LY3437943.

Is retatrutide FDA approved?

No. As of the most recent public data, retatrutide is still in Phase 3 clinical trials. It is not approved by the FDA for any use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only, not for human consumption.

How is retatrutide stored?

Unopened vials are stored at 2-8°C (refrigerator temperature) and stay stable for 12+ months. Once reconstituted with bacteriostatic water, the solution is kept at 2-8°C and used within 28-30 days.


Purity Guarantee

Every batch is ≥99% purity. Send us a COA from any independent test and we’ll issue store credit regardless of what it shows.